Axitinib, a new therapeutic option in renal cell carcinoma - PubMed (original) (raw)
Review
Axitinib, a new therapeutic option in renal cell carcinoma
E R Kessler et al. Drugs Today (Barc). 2012 Oct.
Abstract
Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth factor receptor and proto-oncogene c-Kit. Improved knowledge of kidney cancer development, and specifically mutations in the VHL gene, has supported the targeting of angiogenesis pathways. Axitinib is the most recently approved agent for use in metastatic renal cell carcinoma. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma.
Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.
Similar articles
- Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R, Pickering L, Larkin J. Goldstein R, et al. Expert Rev Anticancer Ther. 2010 Oct;10(10):1545-57. doi: 10.1586/era.10.134. Expert Rev Anticancer Ther. 2010. PMID: 20942625 Review. - Axitinib for the treatment of metastatic renal cell carcinoma.
Parekh H, Griswold J, Rini B. Parekh H, et al. Future Oncol. 2016 Feb;12(3):303-11. doi: 10.2217/fon.15.322. Epub 2016 Jan 15. Future Oncol. 2016. PMID: 26769075 Review. - Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.
Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, Miura M, Habuchi T. Igarashi R, et al. Med Oncol. 2018 Mar 9;35(4):51. doi: 10.1007/s12032-018-1113-8. Med Oncol. 2018. PMID: 29524031 Clinical Trial. - Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C, Lau C, Josephson DY, Pal SK. Carmichael C, et al. Clin Adv Hematol Oncol. 2012 May;10(5):307-14. Clin Adv Hematol Oncol. 2012. PMID: 22706540 Review. - Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. Bellesoeur A, et al. Drug Des Devel Ther. 2017 Sep 21;11:2801-2811. doi: 10.2147/DDDT.S109640. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 29033542 Free PMC article. Review.
Cited by
- Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy.
Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Ammendola M, et al. Biomed Res Int. 2014;2014:154702. doi: 10.1155/2014/154702. Epub 2014 Sep 11. Biomed Res Int. 2014. PMID: 25295247 Free PMC article. Review. - Emerging tyrosine kinase inhibitors for head and neck cancer.
Long Z, Grandis JR, Johnson DE. Long Z, et al. Expert Opin Emerg Drugs. 2022 Sep;27(3):333-344. doi: 10.1080/14728214.2022.2125954. Epub 2022 Sep 21. Expert Opin Emerg Drugs. 2022. PMID: 36131561 Free PMC article. Review. - Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis.
Wang L, Liu WQ, Broussy S, Han B, Fang H. Wang L, et al. Front Pharmacol. 2024 Jan 4;14:1307860. doi: 10.3389/fphar.2023.1307860. eCollection 2023. Front Pharmacol. 2024. PMID: 38239196 Free PMC article. Review. - Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization.
Weiss A, van Beijnum JR, Bonvin D, Jichlinski P, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Weiss A, et al. J Cell Mol Med. 2014 Mar;18(3):480-91. doi: 10.1111/jcmm.12199. Epub 2014 Jan 22. J Cell Mol Med. 2014. PMID: 24450440 Free PMC article. - The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy.
De Wolf K, Vermaelen K, De Meerleer G, Lambrecht BN, Ost P. De Wolf K, et al. Oncoimmunology. 2015 May 27;4(10):e1042198. doi: 10.1080/2162402X.2015.1042198. eCollection 2015 Oct. Oncoimmunology. 2015. PMID: 26464810 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical